Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

Research output: Contribution to journalJournal articleResearchpeer-review

  1. SARS-CoV-2 Production in a Scalable High Cell Density Bioreactor

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies

    Research output: Contribution to journalReviewResearchpeer-review

  3. The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Risk of anal high-grade squamous intraepithelial lesions among renal transplant recipients compared with immunocompetent controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Human papillomavirus genotype-specific risks for cervical intraepithelial lesions

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Expanding our understanding of ovarian cancer risk: the role of incomplete pregnancies

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Sven-Eric Olsson
  • Susanne K Kjaer
  • Kristján Sigurdsson
  • Ole-Erik Iversen
  • Mauricio Hernandez-Avila
  • Cosette M Wheeler
  • Gonzalo Perez
  • Darron R Brown
  • Laura A Koutsky
  • Eng Hseon Tay
  • Patricia García
  • Kevin A Ault
  • Suzanne M Garland
  • Sepp Leodolter
  • Grace W K Tang
  • Daron G Ferris
  • Jorma Paavonen
  • Matti Lehtinen
  • Marc Steben
  • F Xavier Bosch
  • Joakim Dillner
  • Elmar A Joura
  • Slawomir Majewski
  • Nubia Muñoz
  • Evan R Myers
  • Luisa L Villa
  • Frank J Taddeo
  • Christine Roberts
  • Amha Tadesse
  • Janine Bryan
  • Roger Maansson
  • Scott Vuocolo
  • Teresa M Hesley
  • Alfred Saah
  • Eliav Barr
  • Richard M Haupt
View graph of relations
In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL/SILGARD) clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical disease. Of the remaining women, 15% of had evidence of past infection with one or more vaccine HPV types (seropositive and DNA negative) at the time of enrollment. Here we present an analysis in this group of women to determine the efficacy of the HPV 6/11/16/18 vaccine against new cervical and external anogenital disease related to the same vaccine HPV type which had previously been cleared. Vaccine tolerability in this previously infected population was also assessed.
Original languageEnglish
JournalHuman Vaccines
Volume5
Issue number10
Pages (from-to)696-704
Number of pages9
ISSN1554-8600
Publication statusPublished - 1 Oct 2009

ID: 32315413